Lapperre TS[au] - Search Results

Year	Number of Results
1999	2
2004	1
2005	1
2006	4
2007	4
2008	1
2009	1
2011	1
2012	3
2013	1
2014	2
2015	3
2017	7
2018	4
2019	4
2020	8
2021	3

1

Guideline for the management of COVID-19 patients during hospital admission in a non-intensive care setting.

Nielsen Jeschke K, Bonnesen B, Hansen EF, Jensen JS, Lapperre TS, Weinreich UM, Hilberg O. Nielsen Jeschke K, et al. Among authors: lapperre ts. Eur Clin Respir J. 2020 May 28;7(1):1761677. doi: 10.1080/20018525.2020.1761677. Eur Clin Respir J. 2020. PMID: 33224450 Free PMC article. Review.

2

Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.

Sivapalan P, Ulrik CS, Bojesen RD, Lapperre TS, Eklöf JV, Håkansson KEJ, Browatzki A, Tidemansen C, Wilcke JT, Janner J, Gottlieb V, Meteran H, Porsbjerg C, Madsen BL, Moberg M, Pedersen L, Benfield TL, Lundgren JD, Knop FK, Biering-Sørensen T, Ghanizada M, Sonne TP, Bødtger UCS, Jensen SG, Rasmussen DB, Brøndum E, Tupper OD, Sørensen SW, Alstrup G, Laursen CB, Møller UW, Sverrild A, Jensen JS. Sivapalan P, et al. Among authors: lapperre ts. Trials. 2020 Jun 10;21(1):513. doi: 10.1186/s13063-020-04409-9. Trials. 2020. PMID: 32522282 Free PMC article.

3

Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial.

Sivapalan P, Lapperre TS, Janner J, Laub RR, Moberg M, Bech CS, Eklöf J, Holm FS, Armbruster K, Sivapalan P, Mosbech C, Ali AKM, Seersholm N, Wilcke JT, Brøndum E, Sonne TP, Rønholt F, Andreassen HF, Ulrik CS, Vestbo J, Jensen JS. Sivapalan P, et al. Among authors: lapperre ts. Lancet Respir Med. 2019 Aug;7(8):699-709. doi: 10.1016/S2213-2600(19)30176-6. Epub 2019 May 20. Lancet Respir Med. 2019. PMID: 31122894 Clinical Trial.

4

Fractional exhaled nitric oxide as a predictor of response to inhaled corticosteroids in patients with non-specific respiratory symptoms and insignificant bronchodilator reversibility: a randomised controlled trial.

Price DB, Buhl R, Chan A, Freeman D, Gardener E, Godley C, Gruffydd-Jones K, McGarvey L, Ohta K, Ryan D, Syk J, Tan NC, Tan T, Thomas M, Yang S, Konduru PR, Ngantcha M, d'Alcontres MS, Lapperre TS. Price DB, et al. Among authors: lapperre ts. Lancet Respir Med. 2018 Jan;6(1):29-39. doi: 10.1016/S2213-2600(17)30424-1. Epub 2017 Nov 3. Lancet Respir Med. 2018. PMID: 29108938 Free article. Clinical Trial.

5

The scent of COVID-19: viral (semi-)volatiles as fast diagnostic biomarkers?

Lamote K, Janssens E, Schillebeeckx E, Lapperre TS, De Winter BY, van Meerbeeck JP. Lamote K, et al. Among authors: lapperre ts. J Breath Res. 2020 Jul 21;14(4):042001. doi: 10.1088/1752-7163/aba105. J Breath Res. 2020. PMID: 32599571 No abstract available.

6

"High-Risk" Clinical and Inflammatory Clusters in COPD of Chinese Descent.

Tiew PY, Ko FWS, Narayana JK, Poh ME, Xu H, Neo HY, Loh LC, Ong CK, Mac Aogáin M, Tan JHY, Kamaruddin NH, Sim GJH, Lapperre TS, Koh MS, Hui DSC, Abisheganaden JA, Tee A, Tsaneva-Atanasova K, Chotirmall SH. Tiew PY, et al. Among authors: lapperre ts. Chest. 2020 Jul;158(1):145-156. doi: 10.1016/j.chest.2020.01.043. Epub 2020 Feb 22. Chest. 2020. PMID: 32092320 Free PMC article.

7

The emergence of Aspergillus species in chronic respiratory disease.

Yii AC, Koh MS, Lapperre TS, Tan GL, Chotirmall SH. Yii AC, et al. Among authors: lapperre ts. Front Biosci (Schol Ed). 2017 Jan 1;9:127-138. doi: 10.2741/s477. Front Biosci (Schol Ed). 2017. PMID: 27814579 Review.

8

A clinical prediction model for hospitalized COPD exacerbations based on "treatable traits".

Yii ACA, Loh CH, Tiew PY, Xu H, Taha AAM, Koh J, Tan J, Lapperre TS, Anzueto A, Tee AKH. Yii ACA, et al. Among authors: lapperre ts. Int J Chron Obstruct Pulmon Dis. 2019 Mar 27;14:719-728. doi: 10.2147/COPD.S194922. eCollection 2019. Int J Chron Obstruct Pulmon Dis. 2019. PMID: 30988606 Free PMC article.

9

Changes in Control Status of COPD Over Time and Their Consequences: A Prospective International Study.

Miravitlles M, Sliwinski P, Rhee CK, Costello RW, Carter V, Tan JHY, Lapperre TS, Alcazar B, Gouder C, Esquinas C, García-Rivero JL, Kemppinen A, Tee A, Roman-Rodríguez M, Soler-Cataluña JJ, Price DB; Respiratory Effectiveness Group (REG); following investigators participated in the study. Miravitlles M, et al. Among authors: lapperre ts. Arch Bronconeumol (Engl Ed). 2021 Feb;57(2):122-129. doi: 10.1016/j.arbres.2020.06.003. Epub 2020 Jul 21. Arch Bronconeumol (Engl Ed). 2021. PMID: 32709534 English, Spanish.

10

Predictive value of control of COPD for risk of exacerbations: An international, prospective study.

Miravitlles M, Sliwinski P, Rhee CK, Costello RW, Carter V, Tan JHY, Lapperre TS, Alcazar B, Gouder C, Esquinas C, García-Rivero JL, Kemppinen A, Tee A, Roman-Rodríguez M, Soler-Cataluña JJ, Price DB; Respiratory Effectiveness Group (REG). Miravitlles M, et al. Among authors: lapperre ts. Respirology. 2020 Nov;25(11):1136-1143. doi: 10.1111/resp.13811. Epub 2020 Apr 6. Respirology. 2020. PMID: 32249487 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results